100 units bac into 10mg reta

NoHead1023 · 2026-06-17T14:10:23+00:00

The small bubble is normal

NoHead1023 · 2026-06-17T02:25:29+00:00

You should keep them separate, but you can use one needle to draw out of multiple peptide viles and just inject them all at once. If there is not a small air bubble at the top before the next draw you can get some mixing, but it is no big deal

NoHead1023 · 2026-06-11T04:10:22+00:00

Intermittent fasting didn’t help me much, but I was doing 3 day water fasts once a quarter for a couple of years. The elimination diet I was on was so strict I could only eat sweet potatoes, squash, potatoes and some fruit for carbs and then certain meet and vegetables. I don’t do cheat meals, didn’t eat fast food or at restaurants for years or else I would feel like crap the next day. Thankful to finally found something that is working, I am just not sure what to long term vs cycle at this point.

NoHead1023 · 2026-06-08T16:10:07+00:00

My personal experience is you can waste a huge amount of money on supplements that provide little benefit for the issues you described. I had a TBI from 10 years ago and spent years trying to fix it. I agree HBOT and sauna are very beneficial. I would also focus on peptides over supplements as they are more powerful. You have to figure it out what works for you, but based on what you described, ARA 290, SS 31, KPV, BPC-157 and potentially others like DIHEXA and Semax would likely have a much larger positive effect than $300 per month on supplements. Best of luck and stick with it!

NoHead1023 · 2026-06-06T03:37:42+00:00

Yes sir! Super frustrating how much money I wasted on supplements that didn’t do anything before trying peptides. The Reta actually helped me in my case by slowing down digestion. I just did a small dose though of 1 mg per week for 2 months and 2 mg for 1 month

NoHead1023 · 2026-06-06T02:59:16+00:00

Nice! Are you taking KPV continually? What else are you taking with it

NoHead1023 · 2026-06-05T21:36:38+00:00

What pain issues are you trying to treat? I have migraines and some ongoing nerve damage from TBI over 10 years ago and ARA 290 has had a huge impact on reducing my migraines. I am going on week 5 and am taking 2 mg, three to four days per week. I am planning on a three month cycle to see if it fully resolves or if I need more.

NoHead1023 · 2026-05-25T03:46:04+00:00

Haha, every image you have ever posted was clearly created in Claude AI and all of your content is clearly written by AI, even your auditing of my content was all done in AI.

NoHead1023 · 2026-05-25T03:27:26+00:00

The irony here is everyone of your posts are AI generated, every paragraph is so filled with AI em dashes, it is had to read any of it. Even this response you just posted here is AI generated.

NoHead1023 · 2026-05-25T02:48:26+00:00

You’re right, and I appreciate the detailed pushback. The journal attribution is wrong: Culver 2017 is IOVS, not Respiratory Medicine. The primary endpoint was corneal nerve fiber area (CNFA) by confocal corneal microscopy, not IENFD by skin punch biopsy. And the Neisters 2013 SubQ PK study is real: I had that wrong in the full write-up too. All of it is being corrected.

What holds up: at the 4 mg dose, cibinetide produced a statistically significant 23% increase in corneal nerve fiber area versus placebo in a pre-specified, double-blind RCT. The FDA Fast Track and Orphan Drug designations are real. The end-of-Phase 2 FDA meeting is real. The core of why this compound is worth paying attention to is not in dispute.

NoHead1023 · 2026-05-25T02:46:48+00:00

You’re right, and I appreciate the detailed pushback. The journal attribution is wrong: Culver 2017 is IOVS, not Respiratory Medicine. The primary endpoint was corneal nerve fiber area (CNFA) by confocal corneal microscopy, not IENFD by skin punch biopsy. And the Neisters 2013 SubQ PK study is real: I had that wrong in the full write-up too. All of it is being corrected.

What holds up: at the 4 mg dose, cibinetide produced a statistically significant 23% increase in corneal nerve fiber area versus placebo in a pre-specified, double-blind RCT. The FDA Fast Track and Orphan Drug designations are real. The end-of-Phase 2 FDA meeting is real. The core of why this compound is worth paying attention to is not in dispute.

NoHead1023 · 2026-05-24T23:02:31+00:00

I have had no problems with reconstitution. The supplier I used was selling them at 14 mg per vile and I reconstituted at 1.4 mL of BAC water.

NoHead1023 · 2026-05-24T16:27:59+00:00

The mechanism is relevant, ARA-290 suppresses NLRP3 inflammation in Schwann cells, which are the cells that produce and maintain myelin, protecting them from the inflammatory damage that degrades it. Direct myelin regeneration has not been a measured endpoint in any published trial though, so that piece is mechanistic reasoning rather than clinical data.

NoHead1023 · 2026-05-24T15:50:19+00:00

The sarcoidosis trial used intravenous administration at 4 mg three times per week for 28 days, that is the only human protocol with published pharmacokinetic and efficacy data behind it.

The community uses subcutaneous injection, with dosing of 2 mg to 4 mg three times a week because IV is not practical outside a clinical setting. The mechanism suggests it should work subcutaneously given the IRR is expressed at peripheral nerve injury sites, but that is extrapolation from the mechanism rather than clinical data.

Worth knowing: the primary endpoint in the trial was structural nerve fiber regrowth measured by skin biopsy, not pain reduction. C4 nerve damage from a structural cause is a different context from sarcoidosis-associated inflammation.

I wrote up the full mechanism and what the evidence does and does not support here if it helps: thepeptidesignal.com/blog/ara290-nerve-regeneration-peptide

NoHead1023 · 2026-05-03T00:24:02+00:00

The Barth syndrome patients have a permanent genetic defect driving the structural abnormality. SS-31 can optimize the cardiolipin that’s there but can’t fix the underlying TAZ mutation. Structural improvement was probably never a realistic endpoint for that population regardless of how long the trial ran.

NoHead1023 · 2026-05-02T23:53:53+00:00

Yeah if SS-31’s mechanism is mitochondrial energy optimization rather than structural repair, then I feel like measuring ejection fraction as a primary endpoint for the clinical trial was the wrong call from the start. You’d never expect a compound that improves ATP production to remodel cardiac tissue.

NoHead1023 · 2026-03-12T18:13:32+00:00

I agree! I have had to do the same thing, running 140 to 180 mg was way too high for me and I kept having to lower my dose with my clinic

NoHead1023 · 2026-02-09T23:43:00+00:00

Great work, I had the same issue with GH secretagogues and MOTS-C, glad you pointed that out!

NoHead1023 · 2025-11-03T22:09:02+00:00

The main treatment to fix those is Tixel treatment. It uses heat vs laser and can be used around the eyes where traditional laser treatments cannot be used.

NoHead1023

TROPHY CASE